The study is being conducted by Japanese drugmaker Shionogi, which formed a strategic partnership with Akili in 2019 to bring digital therapeutics (DTx) to Asian markets. The ADHD app – renamed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback